Main Logo
  • About Us
    • Our Philosophy
    • The Industry and Us
  • Our Strategy
    • Our Technology
    • Key Applications
    • Clinical Programs
    • Preclinical Programs
    • Pipeline
    • Our Partnerships
  • Our Team
    • Executive Management
    • Board of Directors
    • Clinical Advisory Board
  • Media / Science Center
  • Contact Us
  • Investors

Press Releases

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
    • In The News
    • Videos
  • Events & Presentations
    • Events
    • Presentations
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Filings & Financials
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Management Team
  • Investor Resources
    • Contacts
    • Email Alerts
    • FAQs
    • Investor Fact Sheet
  • News

  • Press Releases
  • Email Alerts
  • In The News
  • Videos
Jun 06, 2023 8:05am EDT

Ensysce Biosciences to Participate in Upcoming Industry Events

May 15, 2023 4:30pm EDT

Ensysce Biosciences Reports First Quarter 2023 Financial Results

May 12, 2023 4:40pm EDT

Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering

May 10, 2023 8:00am EDT

Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering

May 09, 2023 8:00am EDT

Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection

Apr 19, 2023 9:25am EDT

Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development

Apr 11, 2023 8:10am EDT

Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website

Apr 03, 2023 8:00am EDT

Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614

Mar 30, 2023 5:37pm EDT

Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 22, 2023 8:05am EDT

Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • …
  • Page 19
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Main Logo

Biotech company committed to stemming the prescription drug abuse epidemic.

Our proprietary prodrug technologies are designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription drug abuse.

About Us

  • Our philosophy
  • The Industry and Us

Our strategy

  • Our Technology
  • Key Applications
  • Clinical Programs
  • Preclinical Programs
  • Pipeline
  • Our Partnerships

Our Team

  • Executive Management
  • Board of Directors
  • Clinical Advisory Board

Contact Us

Investors

Follow Ensysce on social media:

  • /company/Ensyscebio
  • @Ensyscebio
  • /Ensyscebio